InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Slated to Report Preclinical Data on Lead Candidate at Upcoming Scientific Congresses

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, will be presenting its research at upcoming gatherings for two prestigious organizations. Company researchers will discuss preclinical data supporting the differentiated mechanism of action (“MOA”) for its lead product candidate, PH94B. The research is based on the company’s study, “Brain and Peripheral Distribution of Intranasal Radiolabeled PH94B in Laboratory Rats,” which examines the fundamentally differentiated mechanism of action for PH94B. VistaGen is currently studying PH94B in multiple phase 3 trials focusing on the acute treatment of anxiety in adults with social anxiety disorder (“SAD”). According to the announcement, VTGN vice president of translational medicine Louis Monti, MD, PhD, will present at the annual meeting of the Society of Biological Psychiatry on April 30, 2022, at 3 p.m. PT, and at the annual meeting of the American Society of Clinical Psychopharmacology held in June. “VistaGen is committed to transforming the existing standards of treatments for anxiety and depression disorders,” said VistaGen CEO Shawn Singh in the press release. “As these preclinical data demonstrate, the proposed mechanism of action of our phase 3 clinical candidate, PH94B, is fundamentally unique from all currently available anti-anxiety therapies. In the pandemic years alone, mental health crisis incidents have tripled, making it clear that patients need options that are faster, safer and more tolerable than the current products on the market. Our ongoing PALISADE phase 3 rogram for SAD is designed to assess PH94B’s potential to address that need.”

To view the full press release, visit https://ibn.fm/U4cC4

About VistaGen Therapeutics Inc.

VistaGen is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company is advancing therapeutics with the potential to be faster acting and with fewer side effects and safety concerns than those that are currently available. VistaGen’s clinical-stage candidates are targeting multiple forms of anxiety and depression. These candidates belong to a new class of drugs known as pherines, which are odorless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen’s lead candidate, PH94B, is a nasally administered spray currently in multiple phase 3 trials in the United States, with results anticipated in 2022. Should ongoing phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. With an experienced leadership team and a steady flow of near- and long-term potential milestones, VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression. For more information about the company, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.